IL17A and chronic obstructive pulmonary disease: Although limited by small sample size, these proof-of-concept analyses suggest that our airway epithelial signature of IL-17 response in COPD may mark FEV1 response to ICS better than easily measured cell differentials or other genomic markers of the adaptive immune response.